Wells Fargo & Company Has Lowered Expectations for MannKind (NASDAQ:MNKD) Stock Price

MannKind (NASDAQ:MNKD) had its target price cut by research analysts at Wells Fargo & Company from $8.00 to $7.00 in a report released on Friday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 114.40% from the company’s previous close.

MNKD has been the topic of several other reports. Zacks Research lowered shares of MannKind from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 10th. Truist Financial set a $9.00 price objective on MannKind in a research note on Monday, November 24th. Royal Bank Of Canada reissued a “sector perform” rating and set a $3.50 target price on shares of MannKind in a research note on Friday. Wall Street Zen upgraded shares of MannKind from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of MannKind in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.21.

MannKind Price Performance

Shares of MNKD stock traded up $0.03 during trading hours on Friday, reaching $3.27. The company had a trading volume of 3,816,768 shares, compared to its average volume of 5,131,020. MannKind has a 1-year low of $2.93 and a 1-year high of $6.51. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of 32.65 and a beta of 0.84. The company has a 50 day moving average of $5.61 and a 200 day moving average of $5.35.

MannKind (NASDAQ:MNKD) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.04). MannKind had a net margin of 9.32% and a negative return on equity of 49.33%. The company had revenue of $111.96 million during the quarter, compared to analyst estimates of $99.85 million. During the same period in the previous year, the company posted $0.03 EPS. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. As a group, sell-side analysts forecast that MannKind will post 0.1 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Michael Castagna sold 107,920 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $5.57, for a total transaction of $601,114.40. Following the completion of the sale, the chief executive officer owned 2,504,792 shares in the company, valued at $13,951,691.44. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Stuart A. Tross sold 47,006 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $6.33, for a total value of $297,547.98. Following the completion of the transaction, the insider directly owned 985,007 shares in the company, valued at $6,235,094.31. The trade was a 4.55% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 262,846 shares of company stock valued at $1,546,840. Company insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On MannKind

A number of institutional investors have recently modified their holdings of MNKD. Rubric Capital Management LP acquired a new position in shares of MannKind in the third quarter valued at about $61,297,000. Frazier Life Sciences Management L.P. bought a new stake in MannKind in the 4th quarter valued at about $23,956,000. State Street Corp grew its position in shares of MannKind by 36.2% during the 4th quarter. State Street Corp now owns 14,623,269 shares of the biopharmaceutical company’s stock worth $82,914,000 after purchasing an additional 3,883,071 shares in the last quarter. UBS Group AG increased its holdings in shares of MannKind by 146.7% during the third quarter. UBS Group AG now owns 5,194,739 shares of the biopharmaceutical company’s stock worth $27,896,000 after purchasing an additional 3,088,820 shares during the period. Finally, Wellington Management Group LLP raised its position in shares of MannKind by 316.2% in the third quarter. Wellington Management Group LLP now owns 3,467,721 shares of the biopharmaceutical company’s stock valued at $18,622,000 after buying an additional 2,634,533 shares in the last quarter. Institutional investors own 49.55% of the company’s stock.

Key MannKind News

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Large bullish options activity was reported, suggesting speculative/hedged buying interest that can support near‑term upside. Read More.
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and $11.00 price target, a substantially higher long‑term upside projection that can attract growth‑oriented investors. Read More.
• Positive Sentiment: Company update highlights a modeled $450M 2026 revenue run rate and preparations for an Afrezza pediatric launch — clear product/catalyst milestones that underpin revenue growth expectations. Read More.
• Positive Sentiment: Q4 revenue of ~$112M beat consensus and grew ~46% year‑over‑year (Furoscix sales showed strong growth), supporting the company’s revenue momentum narrative. Read More.
• Neutral Sentiment: Royal Bank of Canada reaffirmed a “sector perform” rating with a $3.50 price target — a modestly supportive but cautious view that implies limited near‑term upside from current levels. Read More.
• Neutral Sentiment: Company filed earnings materials, slide deck and earnings‑call transcript (useful for investors doing deeper diligence on guidance, margins and product timelines). Read More. · Read More.
• Negative Sentiment: EPS missed expectations (reported loss $0.05 vs. consensus loss of $0.01) and the company posted an unexpected quarterly loss, which pressured sentiment and valuation multiples. Read More.
• Negative Sentiment: Market commentary flagged the earnings miss as the reason for a sell‑off and volatility; analysts and traders focused on the bottom‑line deterioration despite top‑line strength. Read More.
• Negative Sentiment: Shares hit a 52‑week low on the earnings reaction, indicating weak near‑term technical momentum and increased downside risk for short‑term traders. Read More.
• Negative Sentiment: Competitive pressure reported — United Therapeutics weighing a new treprostinil formulation — has added sector‑specific risk that could weigh on partner/product expectations. Read More.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.